A CDC report finds that the risk of COVID-19 infection among those fully vaccinated is 0.01%; HHS announce it is designating $4.8 billion to cover COVID-19 testing for uninsured US residents; European Union seeks significant fine for AstraZeneca over breach of vaccine supply contract.
As the United States reached a milestone this week with more than half of US adults now fully vaccinated against COVID-19, a report issued by the CDC finds that the risk of infection among these populations is 0.01%. According to ABC News, reported cases of breakthrough infections, defined as when a fully vaccinated individual becomes infected with SARS-CoV-2, can still occur because vaccines do not provide 100% protection. Currently, 10,262 breakthrough infections have been reported, of which 10% have required hospitalization and 2% have led to death among mostly elderly adults older than 80 years.
As reported by The Hill, HHS announced yesterday it is designating $4.8 billion of funding from the American Rescue Plan to provide relief funding for COVID-19 testing to uninsured US residents. Covering approximately 29 million Americans without insurance, the move will allow providers to bill the program directly for any COVID-19 tests administered to these populations, as well as aid efforts to track and address where the virus is prevalent.
After taking AstraZeneca to court last month over a disparity in the distribution of its COVID-19 vaccine, a lawyer of the European Union said it is seeking a significant fine for the manufacturer. According to Reuters, AstraZeneca had said it would aim to deliver 100 million doses of its COVID-19 vaccine by the end of June, falling short of the 300 million that was noted in the supply contract. The lawyer, Rafael Jafferali, said the European Union is seeking 10 euros or $12.20 for each day of delay for each dose, along with an additional penalty of at least 10 million euros for each breach of contract that the judge will decide. A verdict is expected next month.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More